- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05091684
Administration of Fibrinogen Concentrate for Refractory Bleeding (FORMAT)
March 1, 2024 updated by: Centre Hospitalier Universitaire de Saint Etienne
Administration of Fibrinogen Concentrate for Refractory Bleeding in Hematological Patients With Intensive Chemotherapy-induced Thrombocytopenia - Analysis Using Viscoelastic Haemostatic Assay (FORMAT)
Platelet transfusions are widely employed to prevent or treat bleeding episodes in patients with thrombocytopenia.
Patients with bone marrow failure secondary to haematological malignancy and chemotherapy frequently receive prophylactic platelet transfusion when platelet level reaches 10x109.L-1, to avoid spontaneous major bleeding.
Due to immune or nonimmune factors, platelet refractoriness may be observed and is defined as a repeated suboptimal response to platelet transfusions with lower-than-expected post-transfusion count increments.
The management of patients with alloimmunization is complex and prophylactic platelet support is no longer indicated.
Therefore, platelet refractoriness remains a clinically challenging complication.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
To date, no specific therapeutic strategy has been proposed for platelet refractoriness, in cancer patients who are both at high risk of bleeding and thrombosis.
Interestingly, fibrinogen is a critical hemostatic protein required for both prevention and treatment of bleeding as it provides a matrix and mesh network essential for clot formation, amplification and strength.
Fibrinogen repletion, primarily with the use of fibrinogen concentrates for acquired bleeding, has been reported in clinical settings including surgery, trauma, and obstetrics.
However, its use as adjuvant therapy for patients requiring massive transfusion is not yet a widely approved indication, especially in hematological patients.
Therefore, the evidence regarding timing, efficacy and safety of fibrinogen administration in massively transfused hematological patients is scarce.
This study aims at evaluating whether fibrinogen administration to transfused and refractory patients with on-going bleeding could affect the viscoelastic test of clotting function.
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emilie Chalayer, MD, PhD
- Phone Number: +33 0477917089
- Email: emilie.chalayer@chu-st-etienne.fr
Study Contact Backup
- Name: Elisabeth Daguenet, PhD
- Phone Number: +33 0477917089
- Email: elisabeth.daguenet@chu-st-etienne.fr
Study Locations
-
-
-
Saint-Étienne, France, 42055
- Recruiting
- CHU DE SAINT-ETIENNE
-
Contact:
- Emilie Chalayer, MD, PhD
- Phone Number: +33 0477917089
-
Principal Investigator:
- Emilie Chalayer, MD, PhD
-
Sub-Investigator:
- Caroline Le Jeune
-
Sub-Investigator:
- Emmanuelle Tavernier
-
Sub-Investigator:
- Denis Guyotat
-
Sub-Investigator:
- Ludovic Fouillet
-
Sub-Investigator:
- Fressia Honeyman
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patient affiliated to a social security regimen or beneficiary of the same
- Signed written informed consent form
- Confirmed diagnosis of a hematological malignancy and undergoing intensive chemotherapy, autologous stem cell transplantation or allogeneic stem cell transplantation
- Grade ≥ II hemorrhagic symptoms according to WWorld Health Organization classification
- Failure or impossibility to use Human Leucocyte Antigen-matched platelet unit
- Body weight between 38 and 78 Kgs
- Transfusion refractoriness as defined by Corrected count increment ≤ 5 and platelet level < 20.109.L-1
Exclusion Criteria:
- Pregnant women
- Patient under guardianship or deprived of his liberty or any condition that may affect the patient's ability to understand and sign the informed consent
- Refusing participation
- Patient presenting non-malignant hematological disease
- Patient with high plasmatic concentration of fibrinogen (>5g/L)
- Patient who received fibrinogen within 20 days before inclusion
- Contra-indication to fibrinogen (fibrinogen concentrate) or any excipient (fibrinogen concentrate)
- Patient with disseminated intravascular coagulopathy
- Patient with thromboembolic history
- Patient who received L-Asparaginase or acquired hypofibrinogenemia following treatment by L-Asparaginase
- Patient with known risk of thrombophilia (deficiency for antithrombin 3, C protein or factor V)
- Patient with anti-thrombotic treatment (anti-platelet or anti-coagulant therapy) at the time of enrolment
- Elevated body temperature ≥ 38.5°C
- Hospital stay for invasive surgery
- Patient with acute myeloid leukemia during the induction phase of chemotherapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fibrinogen
Patients with refractory thrombocytopenia, following intensive chemotherapy, and presenting grade ≥ 2 hemorrhagic symptoms, will receive adjuvant fibrinogen administration and platelet transfusions.
|
Refractory transfused patients who present grade ≥ 2 hemorrhagic symptoms will receive a single injection of fibrinogen concentrate (1.5g) followed by platelet transfusion within 2 hours.
Blood sampling will be done at different time points to measure clot viscoelasticity: at baseline, after fibrinogen injection, after platelet transfusion and the day after transfusion or before the next platelet transfusion if < 24 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximal clot elasticity (viscoelastic test of clotting function)
Time Frame: 3 hours
|
Measurement of viscoelastic test of clotting function represented by the maximal clot elasticity based on the maximal clot firmness from the EXTEM (EXtrinsically activated test) curve, between blood sampling before fibrinogen administration and blood sampling after platelet transfusion
|
3 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of viscoelastic test of clotting function before and after treatment using EXTEM (EXtrinsically activated test) and FIBTEM (fibrin clot obtained by platelet inhibition with cytochalasin D) curves (Fibrinogen)
Time Frame: 24 hours
|
Measurement of viscoelastic test of clotting function to determine the contribution of fibrinogen in clotting (before fibrinogen, after fibrinogen, after fibrinogen + platelet transfusion)
|
24 hours
|
Comparison of viscoelastic test of clotting function before and after treatment using EXTEM (EXtrinsically activated test) and FIBTEM (fibrin clot obtained by platelet inhibition with cytochalasin D) curves (platelets)
Time Frame: 24 hours
|
Measurement of viscoelastic test of clotting function to determine the contribution of platelets in clotting (baseline, after fibrinogen + platelet transfusion)
|
24 hours
|
Comparison of viscoelastic test of clotting function before and after treatment using EXTEM (EXtrinsically activated test) and FIBTEM (fibrin clot obtained by platelet inhibition with cytochalasin D) curves (platelets)
Time Frame: 24 hours
|
Measurement of viscoelastic test of clotting function and comparison depending on platelet characteristics
|
24 hours
|
Incidence of hemorrhagic and thrombotic events
Time Frame: 2 months
|
Proportions of patients experiencing bleeding and thrombotic events
|
2 months
|
Incidence of adverse events
Time Frame: 2 months
|
Proportions of patients experiencing adverse events
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Emilie Chalayer, MD, PhD, CHU DE SAINT-ETIENNE
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 10, 2022
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
March 1, 2025
Study Registration Dates
First Submitted
October 13, 2021
First Submitted That Met QC Criteria
October 13, 2021
First Posted (Actual)
October 25, 2021
Study Record Updates
Last Update Posted (Estimated)
March 4, 2024
Last Update Submitted That Met QC Criteria
March 1, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021-0201
- 2021-000990-10 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bleeding
-
Ethicon, Inc.Guangzhou Bioseal Biotechnology Co., Ltd.Completed
-
Waihong ChungUnknownMetoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy (MANPURSE)Upper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Ottawa Hospital Research InstituteRecruitingGastroIntestinal Bleeding | Anticoagulant-induced BleedingCanada
-
Ethicon, Inc.CompletedHemorrhage | Soft Tissue Bleeding | Hepatic Parenchyma BleedingUnited Kingdom, Belgium
-
Hyloris DevelopmentsRecruitingBleeding From Teeth | Bleeding ProphylaxisSpain, United States, Belgium, Croatia, Hungary, Romania
-
Boston Children's HospitalBaylor College of Medicine; Children's Hospital of Philadelphia; Ann & Robert... and other collaboratorsRecruitingUpper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Chinese University of Hong KongCompletedGastrointestinal Bleeding | Bleeding Peptic Ulcer | Active BleedingChina
-
Wake Forest University Health SciencesCompletedBleeding ComplicationUnited States
-
Chinese University of Hong KongBeijing Friendship Hospital; The First Affiliated Hospital of Soochow University and other collaboratorsCompletedAcute Upper Gastrointestinal Bleeding | Tumor BleedingHong Kong, China, Australia
-
Women and Infants Hospital of Rhode IslandActive, not recruitingAbnormal Uterine Bleeding | Abnormal Uterine Bleeding, Ovulatory Dysfunction | Abnormal Uterine Bleeding, Endometrial Hemostatic DysfunctionUnited States
Clinical Trials on Fibrinogen Concentrate Human
-
Medical University InnsbruckCompletedTrauma | Massive HemorrhageAustria, Czech Republic, Germany
-
University of VirginiaOctapharmaCompletedBleeding | Pediatric HDUnited States
-
Laboratoire français de Fractionnement et de BiotechnologiesCompletedHypofibrinogenemia, Congenital | Afibrinogenemia, CongenitalFrance, Lebanon, Morocco, Turkey
-
BiotestAccovion GmbH; ICON plc; SYNLAB Analytics and Services Germany GmbH; Phoenix Clinical... and other collaboratorsCompletedCongenital Afibrinogenemia | Congenital HypofibrinogenemiaBulgaria, Egypt, Germany, Lebanon, Tunisia
-
Laboratoire français de Fractionnement et de BiotechnologiesCompleted
-
Grifols Therapeutics LLCInstituto Grifols, S.A.CompletedCongenital AfibrinogenemiaIndia, United States, Italy, Lebanon
-
CSL BehringCompleted
-
University Children's Hospital, ZurichCompletedHemorrhage | Blood Coagulation DisordersSwitzerland
-
Nicklaus Children's Hospital f/k/a Miami Children...CompletedAfibrinogenemia | Hypofibrinogenemia | Bleeding DisordersUnited States
-
BiotestPRA Health SciencesCompletedBleeding Disorder | Hypofibrinogenemia; AcquiredBelgium, Czechia, Germany, Poland, Spain, Switzerland, United Kingdom